Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficiency of Beijing Protocol in Malignant Hematologic Disease Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

NCT05921318 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05921318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05921318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficiency of Beijing Protocol in Malignant Hematologic Disease Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Unknown status
Start date
June 1, 2023
Completion date
May 31, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancy, stem cell transplant complications